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Abstract: Type 2 diabetes is a progressive disease associated with high levels of morbidity 
and mortality and for which there is both a large and growing prevalence worldwide. Lifestyle 
advice plus metformin is commonly recommended initially to manage hyperglycemia and to 
minimize the risk of vascular complications. However, additional agents are required when 
glycemic targets cannot be achieved or maintained due to the progressive nature of the disease. 
Repaglinide/metformin fixed-dose combination (FDC) therapy (PrandiMet®; Novo Nordisk, 
Bagsværd, Denmark) has been approved for use in the USA. This FDC is a rational second-line 
therapy given the complementary mechanisms of action of the components. Repaglinide is a 
rapidly absorbed, short-acting insulin secretagogue targeting postprandial glucose excursions; 
metformin is an insulin sensitizer with a longer duration of action that principally regulates 
basal glucose levels. A pivotal, 26-week, randomized study with repaglinide/metformin FDC 
therapy has been conducted in patients experiencing suboptimal control with previous oral 
antidiabetes therapy. Repaglinide/metformin FDC improved glycemic control and weight neu-
trality without adverse effects on lipid profiles. There were no major hypoglycemic episodes 
and patients expressed greater satisfaction with repaglinide/metformin FDC than previous 
treatments. Repaglinide/metformin FDC is expected to be more convenient than individual 
tablets for patients taking repaglinide and metformin in loose combination, and it is expected 
to improve glycemic control in patients for whom meglitinide or metformin monotherapies 
provide inadequate control.
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Introduction
Prevalence and burden
Diabetes mellitus is a challenging global health problem, with a large and growing 
prevalence worldwide and high levels of associated morbidity and mortality. The 
International Diabetes Federation (IDF) currently forecasts that 380 million people 
will have diabetes within 20 years, a rise of 55% from current prevalence estimates.1 
As 85% to 95% of cases of diabetes in the developed world (and higher proportions in 
the developing world) are type 2, the prevalence forecast for type 2 diabetes in 2025 is 
effectively in excess of 323 million people. Similar predictions have been made by the 
World Health Organization.2 The rise in prevalence will in part be due to increased life 
expectancy, as type 2 diabetes is more common in older than younger adults.1 However, 
the rise also reflects ongoing trends towards low levels of physical activity, unhealthy 
diets and excess body weight. The burden of type 2 diabetes is significant for patients, 
their carers and healthcare systems. The IDF has commented, “diabetes is expected to Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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cause 3.8 million deaths worldwide in 2007, about 6% of total 
global mortality, and almost the same as HIV/AIDS.”1 It also 
estimates that “the equivalent of … 23 million years of life 
are lost to disability and reduced quality of life caused by the 
complications of diabetes.” In financial terms, it is believed 
that at least US$232 billion was spent treating and preventing 
diabetes and its   complications globally in 2007, and this is 
expected to rise to over US$302 billion by 2025.
Pathology and symptoms
Type 2 diabetes is characterized by two underlying defects: 
insulin resistance in peripheral tissues and reduced insulin 
secretion due to pancreatic beta cell failure. Insulin resistance 
remains relatively stable during the course of the disease, 
but beta cell function continues to decline and is responsible 
for the progressive nature of type 2 diabetes.3,4 In the early 
stages of beta cell failure there is a reduced insulin response 
to meals, and thus raised postprandial blood glucose levels.5 
Chronic elevation of blood glucose levels thereafter has a 
toxic effect on beta cells, resulting in further reductions in 
insulin secretion and thus a cycle of increased glucose levels 
and beta cell damage. Fasting plasma glucose levels become 
raised as beta cell failure progresses.
The deleterious effects of chronic hyperglycemia are 
not restricted to pancreatic beta cells. There is also a strong 
association with micro- and macrovascular complications6 
and with resultant high levels of mortality and morbidity. The 
macrovascular complications of coronary heart disease and 
stroke, for example, are twice as likely to occur in individuals 
with type 2 diabetes as in those without.7 Of the microvascular 
complications, retinopathy is particularly common, with 74% 
of patients with diabetes developing the complication after 
10 years or more; neuropathy occurs in approximately half 
of patients with diabetes and nephropathy in one third.1
Treatment
Stated simply, a key goal of therapy for type 2 diabetes is to 
achieve and maintain good glycemic control, thus   minimizing 
the risk of diabetes complications. Good glycemic   control is 
generally considered to be a glycated hemoglobin (HbA1c) 
level of , 7.0%8 or , 6.5%,1,9 but there is   increasing 
  emphasis on separate fasting and postprandial plasma 
  glucose targets.9–11 A combination of lifestyle advice (diet 
and   exercise) and metformin is commonly recommended 
as a first-line therapy for the management of hyperglycemia 
for patients with type 2 diabetes.8,9 Weight loss and increased 
activity, the goals of lifestyle advice, are associated with 
significant short- and long-term benefits, and thus form an 
important part of the therapeutic strategy throughout the 
course of the disease. The use of metformin at this early stage 
acknowledges the fact that lifestyle modifications alone are 
rarely sufficient to maintain glycemic control. Metformin 
monotherapy is a highly appropriate first-line pharmaceuti-
cal intervention as it reduces hyperglycemia without con-
comitant hypoglycemia or weight gain – side effects that are 
  problematic with hypoglycemic agents.
As type 2 diabetes is progressive, the repeated appraisal 
of glycemic control is imperative at all stages in the   treatment 
pathway.8,9 Where hyperglycemia persists after first-line 
therapy, it is common practice to add a second agent.
The need for combination therapy
Dual therapy has an important place in the management of 
hyperglycemia in type 2 diabetes. The American Association 
of Clinical Endocrinologists (AACE) and American Col-
lege of Endocrinology (ACE) advise that monotherapy may 
initially be sufficient to achieve glycemic goals in patients 
with HbA1c levels , 7.5%, but that dual therapy should be 
initiated if monotherapy fails.9 For patients with HbA1c levels 
of 7.6% to 9.0%, the AACE/ACE advise starting treatment 
with dual therapy and then progressing to triple and insulin 
therapies thereafter.9
Antihyperglycemic and hypoglycemic drugs with 
  different mechanisms of action are likely to have the 
  greatest efficacy in dual-therapy combinations.8 AACE/ACE 
  recommend that metformin should be the “cornerstone” of 
dual therapy for most patients. For patients with HbA1c levels 
, 7.5%, they recommend (in order) incretin-based therapies, 
glinides or sulfonylureas as second components.9 Glinides 
are   recommended over sulfonylureas because of the need 
to control postprandial glucose excursions in patients with 
HbA1c levels , 7.5% and the better safety profile. For patients 
with HbA1c levels of 7.6% to 9.0%, AACE/ACE   recommend 
(in order) incretin-based therapies, thiazolidinediones, 
  sulfonylureas or glinides as second components.
Combination therapy with metformin (an antihypergly-
cemic drug) and a short-acting insulin secretagogue (an oral 
hypoglycemic drug), such as repaglinide, is a rational 
  dual-therapy option for type 2 diabetes. Metformin regulates 
basal glucose levels and repaglinide targets postprandial 
glucose excursions. The two agents have complementary 
mechanisms of action and both are agents recommended 
by AACE/ACE for the management of hyperglycemia in 
patients with HbA1c levels , 9.0%. Moreover, clinical data 
have shown that improvements in glycemic control with 
a loose combination of repaglinide and metformin over a Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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4- to 5-month period are both statistically significant and 
  clinically relevant, even after adjusting for improvements 
in the monotherapy groups.12
The concomitant use of repaglinide and metformin has 
been approved previously, but experience with other dual 
therapies suggests that fixed-dose combinations (FDCs) can 
provide greater patient compliance and thus better glycemic 
control than loose combinations.13,14 Repaglinide/metformin 
FDC (PrandiMet®; Novo Nordisk, Bagsværd, Denmark) 
was approved by the Food and Drug Administration (FDA) 
in June 2008. Repaglinide/metformin FDC is indicated as 
an adjunct to diet and exercise to improve glycemic control 
in adults with type 2 diabetes mellitus who are already 
treated with a meglitinide and metformin or who have 
inadequate glycemic control on either meglitinide or met-
formin alone.15 An initial review of the pharmacokinetics, 
efficacy and safety of this combination product has been 
published previously.16 This article provides further detail 
and an update following FDA approval and the full publi-
cation of key data. This article also considers the potential 
disadvantages of FDCs as they pertain to the repaglinide/
metformin FDC.
Pharmacology  
and pharmacokinetics
The mechanisms of action of repaglinide and metformin, and 
aspects of their pharmacology and pharmacokinetics, have 
been reviewed previously.16 Additional data are summarized 
here, along with key points from the previous summary for 
appropriate context.
Repaglinide
Repaglinide is a rapidly absorbed, short-acting insulin 
  secretagogue that stimulates insulin secretion in the   presence 
of glucose. Peak plasma levels (Cmax) occur in healthy 
  volunteers and patients within 1 hour of administration.15 
The mean time to reach maximum plasma concentrations is 
unchanged when repaglinide is administered with food, but 
the mean Cmax and area under the time/plasma concentration 
curve (AUC) are reduced by 20% and 12.4%, respectively. 
The mean absolute bioavailability of repaglinide is 56% 
and, after intravenous dosing in healthy volunteers, the 
volume of distribution at steady state is 31 L and the total 
body clearance is 38 L/hour. Protein binding and binding to 
human serum albumin are greater than 98%, and the plasma 
half-life is short (approximately 1 hour). Repaglinide is 
completely metabolized by oxidative biotransformation and 
direct conjugation with glucuronic acid, and the resulting 
metabolites have no antihyperglycemic activity. As CYP2C8 
and CYP3A4 are involved in metabolism, drugs that inhibit 
or induce 2C8 and/or 3A4 may alter the pharmacokinetics 
and pharmacodynamics of repaglinide. These drugs include 
gemfibrozil, trimethoprim, itraconazole, ketoconazole and 
rifampin. Within 96 hours of dosing with 14C-repaglinide, 
approximately 90% of the radiolabel is recovered in the 
feces and approximately 8% in the urine. Only 0.1% of the 
dose is cleared in the urine as parent compound and less 
than 2% in feces.
Metformin
Metformin is an insulin sensitizer that inhibits hepatic 
  glucose output and increases peripheral glucose uptake and 
utilization. Metformin does not affect insulin secretion. In 
healthy volunteers, metformin reaches peak plasma levels 
in 2.8 hours (500 mg or 850 mg tablet).17 Metformin Cmax 
and AUC values are reduced by food (by 40% and 25%, 
  respectively, for a single 850 mg tablet), and the time to 
  maximum plasma concentrations is delayed (by 35 minutes).15 
Under fasting conditions, the absolute bioavailability after 
a 500 mg dose of metformin is approximately 50% to 60%. 
Dose proportionality is not apparent due to decreased 
absorption at higher doses. The high apparent volume of 
distribution following a single 850 mg dose (averaging 
654 ± 358 L) reflects negligible binding to plasma proteins. 
The plasma elimination half-life is 6.2 hours; the longer 
blood elimination half-life of 17.6 hours reflects partition-
ing into erythrocytes. Metformin does not undergo hepatic 
metabolism or biliary excretion but is excreted unchanged 
in the urine. Following oral administration, approximately 
90% of the absorbed drug is eliminated via the renal route 
within the first 24 hours.
Repaglinide/metformin FDC
The bioequivalence and the effects of food on the pharma-
cokinetics of the repaglinide/metformin FDC have been 
investigated in randomized, single-blind, crossover trials 
in healthy volunteers.18,19 Repaglinide and metformin in the 
higher-dose FDC tablet (2 mg/500 mg) were bioequivalent to 
individual 2 mg repaglinide and 500 mg metformin tablets in 
terms of total exposure and Cmax.15,18 Furthermore, repaglinide 
total exposure and Cmax values for the higher-dose FDC tablet 
were twice those for the lower-dose tablet (1 mg/500 mg), 
indicating dose proportionality. In a separate study of 
  volunteers receiving 2 mg/850 mg FDC tablets, food was 
shown to affect metformin AUC and Cmax and repaglinide 
Cmax, but not repaglinide AUC.19Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Efficacy
This section focuses on the recently published full data from 
the large, randomized, open-label trial of the   repaglinide/
metformin FDC. Efficacy data from earlier studies of 
  repaglinide/metformin combination therapy (sometimes 
referred to as ‘loose combination’) are also relevant, but have 
been reviewed previously16 and are therefore summarized 
only briefly here.
Co-administration of repaglinide  
and metformin
Studies involving loose combinations of repaglinide and met-
formin showed that good glycemic control could be attained in 
patients failing to reach glycemic targets with diet and exercise 
only or lifestyle advice with up to two oral antidiabetes treat-
ments. These studies provided a strong rationale for the more 
widespread use of repaglinide plus metformin combination 
therapy.16 Key data from three loose-combination studies 
are summarized in Table 1.12,20–22 In brief, loose-combination 
therapies provided significantly greater reductions in HbA1c 
levels than repaglinide and metformin monotherapies12,20,22 and 
the reduction with one combination therapy was significantly 
greater than the sum of the reductions for the monotherapies 
(Figure 1).12 Reductions in HbA1c levels were also greater with 
repaglinide + metformin than with nateglinide + metformin 
combination therapy.21 Similar effects were apparent for 
comparisons of fasting plasma glucose levels.12,20–22
Repaglinide/metformin FDC therapy
The efficacy of repaglinide/metformin FDC tablets has been 
investigated in a pivotal, 26-week study.23,24 The active 
comparator in this trial was another metformin-based FDC, 
but with an insulin sensitizer, rosiglitazone, rather than an 
insulin secretagogue.
Study design
Participants enrolled into the study had been previously 
receiving up to two oral antidiabetes drugs (for at least 
2 months as monotherapy) and experiencing suboptimal 
glycemic control (HbA1c levels of 7.5% to11.0% for mono-
therapy or 7.0% to 10.0% for dual therapy). Any drug other 
than metformin must have been administered at half-maximal 
doses or less. A total of 561 patients were randomly allocated 
1:1:1 to repaglinide/metformin FDC twice or three times 
daily, or rosiglitazone/metformin twice daily (n = 187 in each 
group). The repaglinide/metformin FDC groups received 
maximum doses of either 4 mg repaglinide/1,000 mg met-
formin at breakfast and supper (twice daily regimen) or 4 mg 
repaglinide/1,000 mg metformin at breakfast and supper and 
2 mg repaglinide/500 mg metformin at lunch (three times 
daily regimen). The rosiglitazone/metformin group received 
maximum doses of 4 mg rosiglitazone/1,000 mg metformin 
at breakfast and supper. Doses were titrated weekly over 
a 4-week period up to the maximum doses. Patients who 
were unable to tolerate dosing were withdrawn from the 
Table 1 Glycemic control in terms of HbA1c levels from key studies involving the co-administration of repaglinide and metformin 
(loose combination) in patients with type 2 diabetes
Reference Patient population Overview of study design Key efficacy findings
Moses et al12  
and Moses et al20
Suboptimal glycemic control  
after 6 months of metformin 
monotherapy
4–5 months of treatment with: 
repaglinide + placebo (n = 29) 
placebo + metformin (n = 27) 
repaglinide + metformin (n = 27)
Mean HbA1c levels significantly reduced from baseline 
with repaglinide + metformin (P , 0.01); reductions 
with monotherapies not significant
Reduction in HbA1c level with repaglinide + metformin 
significantly greater than those with monotherapies 
(P , 0.05 in each case), and reduction numerically 
greater than the sum of the effects for each monotherapy
More patients in the repaglinide + metformin group 
(56%) achieved HbA1c target levels of , 7.0% than in 
the monotherapy groups (19% in each case)
Reboussin et al22 Suboptimal glycemic control  
with diet and exercise or  
with fewer than three OADs
16 weeks of treatment with: 
repaglinide (n = 44) 
repaglinide + metformin (n = 42)
Reductions in HbA1c levels from baseline significant  
for both groups (P , 0.001)
Change from baseline in HbA1c level greater with 
repaglinide + metformin than with repaglinide 
monotherapy (P , 0.05)
Raskin et al21 Suboptimal glycemic control 
with OAD monotherapy 
or glyburide/metformin 
combination therapy
16 weeks of treatment with: 
repaglinide + metformin (n = 96) 
nateglinide + metformin (n = 96)
HbA1c reduction with repaglinide + metformin significantly 
greater than that for nateglinide + metformin (P , 0.001)
More patients in the repaglinide + metformin group 
(59%) achieved HbA1c target levels of # 7.0% than in the 
nateglinide + metformin group (47%)
Abbreviations: HbA1c, glycated hemoglobin; OAD, oral antidiabetes drug.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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study. The efficacy of repaglinide/metformin twice daily was 
compared with those of the other two treatment regimens. 
Parameters assessed included glycemic control (HbA1c and 
fasting plasma glucose levels), body weight, waist:hip ratios 
and lipid profiles. The primary endpoint was the change in 
HbA1c level from baseline to week 26.
Patient disposition and baseline characteristics
A total of 383 (68.3%) patients completed the study. 
  Discontinuation rates were similar across the treatment 
groups, but withdrawal because of ineffective therapy was 
slightly more common with rosiglitazone/metformin and 
withdrawal for adverse events slightly more common with 
repaglinide/  metformin.24 The treatment groups were com-
parable in terms of baseline demographic and disease char-
acteristics. The study population had mean ages across the 
treatment groups of 54.5 to 54.8 years, and mean body mass 
indices of 32 to 33 kg/m2. The mean durations of diabetes 
were 7.1 to 7.4 years and the mean baseline HbA1c values 
were 8.3% to 8.5%.
Repaglinide/metformin FDC twice versus three 
times daily
Both regimens improved HbA1c levels during the study 
(Figure 2), with overall mean reductions from baseline to week 
26 of −0.99% and −1.02% for the twice and three times daily 
regimens, respectively.23 Importantly, the twice daily regi-
men was non-inferior to the three times daily regimen (least 
square mean, 0.122; 95% confidence interval [CI]: −0.104 
to 0.349). Improvements in glycemic control were reflected 
in the proportions of patients reaching target HbA1c levels. 
At week 26, 42.9% and 48.9% of the twice and three times 
daily groups, respectively, had HbA1c levels of # 7.0%. There 
was no significant difference between the treatment regimens 
in terms of the proportions of patients reaching this or the 
#7.5% or #6.5% HbA1c targets. The   pattern of reductions 
in fasting plasma glucose levels was similar to that for HbA1c 
levels (Figure 3). Moreover, the changes from baseline to 
week 26 were not significantly   different for the two regimens 
(P = 0.3472). Mean   reductions in fasting plasma glucose levels 
were −1.13 mmol/L and −1.10 mmol/L for the twice and three 
times daily   regimens, respectively.
In essence, the regimens were weight-neutral, with a 
small mean weight gain of 0.47 kg in the twice daily group 
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compared with a small mean weight loss of −0.34 kg in the 
three times daily group. The difference between the groups 
was statistically significant (P = 0.0333), but not clinically rel-
evant. Moreover, there was no significant difference between 
the two regimens for waist:hip ratios (P = 0.5438). Long-term 
weight-neutrality is expected with repaglinide/metformin 
combination therapy based on extensive clinical experience 
with metformin monotherapy, and 1-year   double-blind clini-
cal trial data with repaglinide monotherapy.25–27
Overall, the efficacy data from the study suggest that 
repaglinide/metformin FDC can be administered in a twice 
or three times daily regimen, depending on individual patient 
needs, without compromising efficacy. This FDC may also 
be an appropriate therapeutic option for patients with type 2 
diabetes who have fears about weight gain when intensifying 
their oral antidiabetes therapy.
Repaglinide/metformin twice daily versus 
rosiglitazone/metformin twice daily
The improvement in HbA1c levels at study end for   repaglinide/
metformin was non-inferior to that for rosiglitazone/  metformin 
(−0.99% and −1.01%, respectively; P = 0.8186).24 During the 
course of the study, however, reductions occurred earlier 
with repaglinide/metformin than rosiglitazone/metformin 
(Figure 4). At week 26, 42.9% and 48.9% of the repaglinide/ 
metformin and   rosiglitazone/metformin groups, respectively, 
had HbA1c levels of # 7.0%. There was no   significant 
  difference between the treatment regimens in terms of the 
proportions of patients reaching this or the #7.5% or #6.5% 
HbA1c targets. Fasting plasma glucose levels improved in both 
treatment groups but rosiglitazone/metformin was associ-
ated with significantly greater reductions than repaglinide/
metformin at weeks 18 and 26 (Figure 5). At week 26, the 
changes for the rosiglitazone/metformin and repaglinide/
metformin groups were −2.04 mmol/L and −1.13 mmol/L, 
respectively (P = 0.004). These   differences between   treatment 
groups may be due to the   mechanisms of action of repaglin-
ide and rosiglitazone.   Repaglinide is a short-acting insulin 
  secretagogue   commonly used to reduce mealtime glucose 
excursions, whereas   rosiglitazone is an insulin sensitizer, 
which may be expected to have a greater effect on fasting 
plasma glucose levels.
Changes in body weight and waist:hip ratios were not 
clinically relevant (,0.5 kg) and not statistically different 
between groups. There were small (although not significant) 
reductions from baseline with repaglinide/metformin for 
all lipids measured but significant increases (P # 0.001) 
with rosiglitazone/metformin for all lipids measured except 
triglycerides.
Over a 26-week period, the repaglinide/metformin and 
rosiglitazone/metformin FDCs used in this study provided 
similar levels of glycemic control in terms of HbA1c levels 
and both were weight-neutral. While rosiglitazone/metformin 
provided better control of fasting plasma glucose levels, there 
were also adverse effects on lipid profiles.
Appraisal of current research
There are currently few studies with repaglinide/metformin 
FDC. The key study reported above was a large, randomized, 
controlled trial and as such provides valuable data about 
the efficacy and safety of repaglinide/metformin FDC. 
The open-label nature of the study may have influenced 
study outcomes, although the key findings are in line with 
expectations based on clinical experience and clinical trial 
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data with loose combination therapy. It is hoped that future 
research will investigate whether the efficacy benefits of repa-
glinide/metformin FDC are maintained in the longer term.
Dosing strategy
The potential benefits afforded by FDCs in terms of patient 
convenience and compliance must be weighed against the 
potential disadvantage of reduced dosing flexibility (such 
that patients are at an increased risk of adverse effects 
without added benefit). Repaglinide/metformin FDC is 
available in two dose strengths, 1 mg repaglinide/500 mg 
metformin and 2 mg repaglinide/500 mg metformin.15 
For patients already taking repaglinide and metformin 
in loose combination, doses should be matched to FDC 
doses. Patients experiencing suboptimal glycemic control 
with metformin or meglitinide monotherapy are candidates 
for dual therapy.9 Where the repaglinide/metformin FDC 
appears the most appropriate choice for that dual therapy, 
treatment should usually be started with the low-dose tablet 
twice daily.15
Physicians will also be familiar, based on their experience 
with other treatment options, with the need to monitor blood 
glucose levels to determine the therapeutic response and 
advise patients on the appropriate use of treatment in relation 
to meals. In the case of the repaglinide/metformin FDC, treat-
ment should be administered within the 15 minutes preceding 
a meal, but the timing can vary from immediately preceding 
the meal to up to 30 minutes before the meal. Patients who 
skip a meal should be advised to skip the dose for that meal. 
Maximum doses are 10 mg repaglinide/2500 mg metformin 
per day or 4 mg repaglinide/1000 mg metformin per meal, 
and treatment can be administered two or three times daily. 
Indeed, data from the clinical study conducted by Raskin and 
colleagues have shown that reductions in HbA1c and fasting 
plasma glucose over 26 weeks with a twice daily regimen 
were not significantly different from those for the three times 
daily regimen.23
Safety and tolerability
individual components
The individual components of the repaglinide/metformin 
FDC are generally well tolerated.28,29 As with all insulin 
secretagogues, repaglinide has the potential to cause hypo-
glycemia. However, the risk of major hypoglycemia with 
repaglinide may be lower than that with sulfonylureas,30 and 
the risk can be minimized by matching the dose with the cor-
rect carbohydrate meal portions and by initiating treatment 
with the lowest available dose in patients naïve to meglitinide 
therapy. Metformin is not associated with hypoglycemia; 
moreover, it lowers blood glucose levels without causing 
weight gain and has neutral-to-positive effects on lipids and 
blood pressure.31
Metformin is associated with more gastrointestinal 
symptoms than other oral antidiabetes drugs (eg, nausea, 
vomiting, diarrhea),32 but these symptoms can be limited 
by reducing the dose and using slow-release formulations. 
Additionally, although metformin accumulation can lead to 
lactic acidosis, this adverse event is rare, with an incidence 
of 0.03 cases/1,000 patient-years of exposure.33 Moreover, 
in more than 20,000 patient-years of exposure to metformin 
in clinical trials, there were no reports of lactic acidosis. 
As metformin is largely excreted by the kidneys, the risk 
of metformin accumulation is greater in patients with renal 
impairment. Metformin is thus contraindicated in patients 
with renal impairment.
The incidence of total serious cardiovascular adverse 
events is 4% for repaglinide and 3% for sulfonylurea drugs 
in 1-year controlled clinical trials.15 Initial data from a 
nationwide study in Denmark among 100,206 patients 
with diabetes without prior myocardial infarction suggest 
repaglinide monotherapy is associated with a risk of car-
diovascular death similar to metformin monotherapy, the 
drug considered to be the safest glucose-lowering agent in 
terms of cardiovascular disease.34 The risks of cardiovascular 
death for acarbose and the sulfonylurea gliclazide were also 
similar to those for metformin, but the risks were higher for 
the other sulfonylureas tested (glimepiride, glibenclamide, 
glipizide and tolbutamide).
Repaglinide/metformin combination 
therapy
Combination therapy is well tolerated. The safety of 
  repaglinide/metformin FDC was investigated in a large, 
26-week study of patients experiencing suboptimal glyce-
mic control with one or two oral antidiabetes drugs.23,24 The 
study had three treatment arms: repaglinide/metformin FDC 
twice or three times daily, and rosiglitazone/metformin FDC 
twice daily. A slightly higher proportion of patients withdrew 
because of adverse events from repaglinide/metformin FDC 
regimens (9.6% and 9.1% for twice and three times daily, 
respectively) than the rosiglitazone/metformin FDC regimen 
(6.4%), but the proportions of patients experiencing adverse 
events overall were similar across treatment arms (54.3%, 
63.4% and 58.9%, respectively). The most common adverse 
events with the twice daily repaglinide/metformin regimen 
were diarrhea (10.6%), headache (6.4%), upper respiratory Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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tract infection (4.8%) and nausea (4.8%). Similar rates were 
observed with the three times daily regimen, although the 
rate for upper respiratory tract infection was lower (2.2%). 
Diarrhea and headache were less common with rosiglitazone/
metformin FDC, but the adverse-event profile was otherwise 
similar. Eleven patients receiving repaglinide/metformin 
FDC experienced serious adverse events, although none 
were considered likely to be related to study medication. One 
patient (twice daily regimen) with a history of   hypertension, 
hyperlipidemia and coronary artery disease died during 
the study, which the investigator considered to be probable 
  sudden cardiac death.
No major hypoglycemic episodes were reported in 
any treatment arm in the 26-week study. The rates of 
minor hypoglycemic events (defined as plasma glucose 
levels , 3.1 mmol/L) were similar for the two repaglinide/ 
metformin regimens (3.79 and 4.46 events/patient/year for 
twice and three times daily, respectively), with over half of 
the events experienced by only 18 patients. The rate of minor 
hypoglycemia was significantly lower in the   rosiglitazone/
metformin FDC treatment arm (0.27 events/patient/year) 
compared with the twice daily repaglinide/metformin 
  treatment arm (Poisson regression P = 0.0003), but most 
patients had only approximately 2 events/year.24 The higher 
rate of hypoglycemia with the repaglinide/metformin FDC 
was not unexpected, as insulin secretagogues have greater 
hypoglycemic potential than thiazolidinediones. As men-
tioned earlier, the risk of hypoglycemia with repaglinide/
metformin FDC therapy can be minimized by matching the 
dose with the correct carbohydrate meal portions and by 
initiating treatment with lowest available dose in patients 
naïve to meglitinide therapy.15 It is also important to skip 
medication when meals are skipped. Data from studies in 
which repaglinide and metformin were used in loose com-
bination are broadly consistent with those from the key FDC 
trial.12,21,22 A higher rate of hypoglycemia was observed with 
combination therapy compared with repaglinide monotherapy 
in the study by Moses and colleagues, but none of the events 
were severe.12
As metformin is a component of the FDC, there is an 
associated risk of lactic acidosis.15 However, lactic aci-
dosis was not reported in studies involving combination 
therapy12,21–24 and the incidence of lactic acidosis with 
metformin overall is rare.33 Repaglinide/metformin FDC, 
as with metformin alone, is contraindicated in patients with 
renal impairment because metformin is largely excreted by 
the kidneys.15
Additional safety information relating to the use of 
repaglinide/metformin FDC is provided in country-specific 
prescribing information. The panel summarizes key points 
of the prescribing information for the USA.
Patient perspective
The successful management of type 2 diabetes depends 
  heavily on the behavior of the patients themselves. Oral agents 
generally compare favorably with injectable therapies used 
later in the disease process in terms of the   perceived   burden, 
but compliance is nonetheless influenced by   treatment-related 
side effects, and the flexibility and   convenience of oral 
antidiabetes regimens. As discussed earlier, the repaglinide/
metformin FDC is generally well tolerated.23 Data suggest 
that both twice and three times daily regimens are weight-
neutral,23 and experience with repaglinide and metformin as 
monotherapies suggests this will be the case in the longer 
term.25–27 Moreover, starting treatment at the lowest doses in 
patients naïve to meglitinide therapy and skipping medica-
tions when meals are skipped will do much to minimize the 
risk of hypoglycemia.15
Panel Key features of the prescribing information for PrandiMet® 
in the USA15
Contraindications Patients with/receiving: 
• renal impairment
•   metabolic acidosis, including diabetes 
ketoacidosis
• both gemfibrozil and itraconazole
warnings and  
precautions
•   Assess renal function before initiating therapy 
and at least annually thereafter, and verify as 
normal
•   Temporarily discontinue therapy in patients 
receiving iodinated contrast for radiological 
studies
•   Do not use in patients with hepatic impairment
•   warn patients against excess alcohol intake
•   Do not use in combination with NPH insulin
•   Co-administration with gemfibrozil is not 
recommended
•   initiate at the lowest available dose in patients 
naïve to meglitinide therapy
•   Measure hematological parameters annually to 
assess vitamin B12 status
•   Discontinue use and temporarily initiate insulin 
if glycemic control deteriorates during periods 
of stress or if there is decreased intake of fluids 
and food (eg, infection, surgery)
•   There have been no clinical studies establishing 
conclusive evidence of macrovascular 
risk reduction with this or any other oral 
antidiabetes drug 
Note: information is applicable only to treatment within the USA.
Abbreviation: NPH, neutral protamine Hagedorn.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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The diabetes treatment satisfaction questionnaire was 
used to gather data on patients’ satisfaction with repaglinide/
metformin FDC therapy as part of the 26-week study compar-
ing a twice daily repaglinide/metformin FDC regimen with 
a three times daily regimen and a twice daily rosiglitazone/
metformin FDC regimen.23,24 Patients’ perceptions of therapy 
were similar for twice daily repaglinide/metformin and twice 
daily   rosiglitazone/metformin,24 and patients were generally 
more satisfied with the FDC therapies than their previous oral 
antidiabetes therapies. Perceptions of therapy were similar 
for the twice and three times daily repaglinide/metformin 
regimens, except that the three times daily group perceived 
hypoglycemia and low glucose readings to be more frequent at 
the end of the study, whereas the twice daily group perceived 
them to be less frequent.23 The frequency of dosing, twice 
or three times daily, is likely to be considered convenient by 
most patients. In a study of patient perceptions of repaglinide 
monotherapy, 18% of the 1233 patients were taking treat-
ment twice daily with meals and 68% three times daily with 
meals.35 Overall, 81% of patients considered treatment to be 
convenient.
How patients’ perceptions of repaglinide/metformin FDC 
therapy translate into treatment adherence has not been assessed. 
However, other FDC products have been shown to provide 
greater patient compliance and thus glycemic control.13,14
Conclusions
The first-line therapy commonly recommended for 
type 2 diabetes is lifestyle advice in combination with 
metformin monotherapy. The subsequent failure of therapy 
is largely due to the progressive nature of type 2 diabetes, 
with continued deterioration of beta cell function leading 
to persistent hyperglycemia. The addition of repaglinide to 
metformin therapy is a rational choice for second-line therapy 
as the two components have complementary mechanisms 
of action. Repaglinide is a rapidly absorbed, short-acting 
insulin   secretagogue, which is intended to address mealtime 
  excursions in blood glucose levels. In contrast, metformin is 
an insulin sensitizer with a longer duration of action, inhibit-
ing hepatic glucose output and increasing peripheral glucose 
uptake and utilization. Metformin is thus predominantly a 
basal glucose regulator. The complementary modes of action 
of repaglinide and metformin suggest that patients with 
inadequate glycemic control with meglitinide or metformin 
monotherapy may achieve improved control with repaglinide/
metformin FDC therapy. FDC therapy may additionally be 
more convenient for patients taking repaglinide and met-
formin in loose combination.
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